| Umsatz in Mio. | 47,98 $ |
| Operatives Ergebnis (EBIT) in Mio. | -73,36 $ |
| Jahresüberschuss in Mio. | -68,57 $ |
| Umsatz je Aktie | 0,89 $ |
| Gewinn je Aktie | -1,27 $ |
| Gewinnrendite | -148,66% |
| Umsatzrendite | - |
| Return on Investment | -62,03% |
| Marktkapitalisierung in Mio. | 55,66 $ |
| KGV (Kurs/Gewinn) | -0,81 |
| KBV (Kurs/Buchwert) | 1,21 |
| KUV (Kurs/Umsatz) | 1,16 |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | +41,72% |
| Geld/Brief | 2,29 $ / 2,33 $ |
| Spread | +1,75% |
| Schluss Vortag | 2,34 $ |
| Gehandelte Stücke | 57.038 |
| Tagesvolumen Vortag | 41.892,07 $ |
| Tagestief 2,275 $ Tageshoch 2,325 $ | |
| 52W-Tief 0,51 $ 52W-Hoch 3,21 $ | |
| Jahrestief 0,51 $ Jahreshoch 3,21 $ | |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Düsseldorf | 1,95 € | -1,42% | 1,978 € | 23.12.25 | |
| Frankfurt | 1,894 € | +0,42% | 1,886 € | 23.12.25 | |
| München | 1,962 € | +0,41% | 1,954 € | 23.12.25 | |
| Stuttgart | 1,962 € | -0,91% | 1,98 € | 23.12.25 | |
| L&S RT | 1,97 € | 0 % | 1,97 € | 19:04 | |
| Berlin | 1,98 € | -1,00% | 2,00 € | 23.12.25 | |
| NYSE | 2,325 $ | -0,64% | 2,34 $ | 26.12.25 | |
| Nasdaq | 2,32 $ | -0,85% | 2,34 $ | 26.12.25 | |
| AMEX | 2,32 $ | 0 % | 2,32 $ | 26.12.25 | |
| Tradegate | 1,952 € | -2,89% | 2,01 € | 23.12.25 | |
| Quotrix | 2,01 € | +1,41% | 1,982 € | 23.12.25 | |
| Gettex | 1,992 € | -0,10% | 1,994 € | 23.12.25 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 26.12.25 | 2,32 | 113 T |
| 24.12.25 | 2,34 | 41.892 |
| 23.12.25 | 2,33 | 122 T |
| 22.12.25 | 2,37 | 109 T |
| 19.12.25 | 2,32 | 139 T |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 2,32 $ | 0,00% |
| 1 Monat | 2,33 $ | -0,43% |
| 6 Monate | 2,90 $ | -20,00% |
| 1 Jahr | 0,9439 $ | +145,79% |
| 5 Jahre | 21,97 $ | -89,44% |
| Marktkapitalisierung | 110,19 Mio. € |
| Aktienanzahl | 55,91 Mio. |
| Streubesitz | 59,58% |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
| +4,20% | Pfizer Inc |
| +3,47% | Vanguard Group Inc |
| +2,87% | Anson Funds Management LP |
| +1,58% | Alphabet Inc |
| +1,48% | Renaissance Technologies Corp |
| +0,91% | Schonfeld Strategic Advisors LLC |
| +0,91% | Geode Capital Management, LLC |
| +0,77% | BlackRock Inc |
| +0,55% | MONIMUS CAPITAL MANAGEMENT, LP |
| +0,42% | The Informed Momentum Company (formerly EAM Investors) |
| +0,28% | Stonepine Capital Management Llc |
| +0,27% | State Street Corp |
| +0,27% | Ionic Capital Management LLC |
| +0,26% | ADAR1 Capital Management LLC |
| +0,20% | Bridgeway Capital Management, LLC |
| +0,18% | Citadel Advisors Llc |
| +0,18% | Northern Trust Corp |
| +0,12% | Susquehanna International Group, LLP |
| +0,06% | XTX Topco Ltd |
| +0,06% | Axxcess Wealth Management, LLC |
| +21,38% | Weitere |
| +59,58% | Streubesitz |
Zahlen für Q4/22
- Initiated proof-of-concept Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); top line data expected in 1H 2024
- to fund its operating expenses and capital expenditure requirements beyond 2024
https://s3.amazonaws.com/b2icontent.irpass.cc/2748/rl117181.pdf